adamantane has been researched along with pioglitazone in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (32.26) | 29.6817 |
| 2010's | 20 (64.52) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, MA; Dejager, S; Garber, AJ; Rochotte, E; Schweizer, A | 1 |
| Baron, MA; Camisasca, RP; Couturier, A; Cressier, F; Dejager, S; Kim, SW; Rosenstock, J | 1 |
| Bolli, G; Cohen, SE; Dotta, F; Rochotte, E | 1 |
| Ahrén, B | 2 |
| Balez, S; Bullock, J; Dole, WP; He, YL; Jarugula, V; Ligueros-Saylan, M; Riviere, GJ; Schwartz, S; Serra, D; Wang, Y | 1 |
| Argyrakopoulou, G; Doupis, J | 1 |
| Mikhail, N | 1 |
| Bolli, G; Colin, L; Dotta, F; Goodman, M; Minic, B | 1 |
| Allen, E; Chen, R; Hollander, P; Li, J | 1 |
| Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Moreira, RO; Nascimento, TS; Zagury, L; Zagury, RL | 1 |
| Boulton, DW; Brenner, E; Handschuh del Corral, M; Komoroski, B; Kornhauser, D; Li, L; Patel, CG; Vachharajani, N | 1 |
| Allen, E; Chen, R; Frederich, R; Hollander, PL; Li, J | 1 |
| Jermendy, G | 1 |
| Frier, BM; Inkster, B; Zammitt, NN | 1 |
| Akhtar, M; Imran, M; Khan, S; Najmi, AK; Pillai, KK | 1 |
| Döller, D; Frantal, S; Haidinger, M; Hecking, M; Lechner, F; Pacini, G; Pleiner, J; Säemann, MD; Stemer, G; Werzowa, J | 1 |
| Iwamura, T; Kainoh, M; Kawai, K; Kumagai, H; Nakaki, J; Nitta, A; Okazaki, S; Sakami, S; Sato, M; Sekiya, Y; Takahashi, T; Yagi, M | 1 |
| Chattipakorn, N; Chattipakorn, SC; Pipatpiboon, N; Pratchayasakul, W; Sripetchwandee, J | 1 |
| Dangi-Garimella, S | 1 |
| Brady, EM; Dales, J; Davies, MJ; Gray, LJ; Hanif, W; Khunti, K | 1 |
| Akhtar, M; Khan, S; Najmi, AK; Panda, BP | 1 |
| Balakrishnan, S; Brown, NJ; Fireman, BH; Graham, DJ; Griffin, MR; Hamilton, J; Hampp, C; Iyer, A; Lendle, S; Nathwani, N; Pimentel, M; Pucino, F; Reichman, ME; Rucker, M; Toh, S | 1 |
| El Sarha, A; Refaat, R; Sakr, A; Salama, M | 1 |
| Eom, YS; Gwon, AR; Kim, BJ; Kim, JY; Kim, KW; Kim, YS; Kwak, KM; Lee, K; Lee, S; Park, IB; Yu, SH | 1 |
| Bundhun, PK; Huang, F; Janoo, G; Teeluck, AR | 1 |
| Butler, MG; Fireman, BH; Graham, DJ; Hamilton, J; Hampp, C; Iyer, A; Lendle, S; Pimentel, M; Reichman, ME; Rucker, M; Toh, S; Zhang, R | 1 |
| Abdelaziz, RR; Abdelhamid, AM; Salem, HAA | 1 |
| Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
| Chin, KL; Hawley, CM; Jun, M; Lo, C; Oshima, M; Toyama, T; Zoungas, S | 1 |
10 review(s) available for adamantane and pioglitazone
| Article | Year |
|---|---|
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2009 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Drug-induced hypoglycaemia in type 2 diabetes.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Peptides; Pharmacogenetics; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2012 |
Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Thrombosis; Vildagliptin | 2013 |
Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Observational Studies as Topic; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Vildagliptin; Weight Loss | 2015 |
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adamantane; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Vildagliptin | 2017 |
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Topics: Adamantane; Bias; Cause of Death; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Glycated Hemoglobin; Graft Survival; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Kidney Transplantation; Nitriles; Pioglitazone; Postoperative Complications; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Transplant Recipients; Vildagliptin | 2020 |
10 trial(s) available for adamantane and pioglitazone
| Article | Year |
|---|---|
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Ligands; Lipids; Male; Middle Aged; Nitriles; Pioglitazone; Proinsulin; Protease Inhibitors; Pyrrolidines; Thiazolidinediones; Treatment Failure; Treatment Outcome; Vildagliptin | 2007 |
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pioglitazone; Protease Inhibitors; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2007 |
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2008 |
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Topics: Adamantane; Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Vildagliptin | 2008 |
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult | 2009 |
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
Topics: Adamantane; Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pancreatic Function Tests; Pioglitazone; Rosiglitazone; Thiazolidinediones; Young Adult | 2009 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vildagliptin | 2010 |
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
Topics: Adamantane; Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Young Adult | 2011 |
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebo Effect; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; United States | 2011 |
Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Transplantation; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Pioglitazone; Pyrrolidines; Risk Factors; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2013 |
11 other study(ies) available for adamantane and pioglitazone
| Article | Year |
|---|---|
Multidrug therapy in a patient with Rabson-Mendenhall syndrome.
Topics: Adamantane; Adolescent; Diabetes Mellitus, Type 2; Donohue Syndrome; Humans; Hypoglycemic Agents; Male; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Vildagliptin | 2010 |
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Carbenoxolone; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Pioglitazone; Thiazolidinediones; Triazoles | 2014 |
DPP-4 inhibitor and PPARγ agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Cholesterol; Dendritic Spines; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Neuroprotective Agents; Nitriles; Obesity; Pioglitazone; PPAR gamma; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Thiazolidinediones; Vildagliptin | 2014 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration | 2014 |
Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus.
Topics: Adamantane; Administration, Oral; Animals; Biomarkers; Diabetes Mellitus, Experimental; Disease Progression; Drug Therapy, Combination; Fibrinogen; Hypoglycemic Agents; Male; Nitriles; Pioglitazone; Platelet Count; Pyrrolidines; Rats; Rats, Sprague-Dawley; Streptozocin; Thiazolidinediones; Thrombosis; Vildagliptin | 2015 |
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
Topics: Adamantane; Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglycemic Agents; Inflammation; Insulin; Kidney; Liver; Male; Nitriles; Oxidative Stress; Pancreas; Pioglitazone; Pyrrolidines; Rats; Rats, Wistar; Thiazolidinediones; Urea; Vildagliptin | 2016 |
Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.
Topics: Adamantane; Animals; Biomarkers; Bone Density; Bone Resorption; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Male; Nitriles; Pioglitazone; Pyrrolidines; Rats; Rats, Zucker; Tartrate-Resistant Acid Phosphatase; Thiazolidinediones; Vildagliptin | 2016 |
Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study.
Topics: Acute Disease; Adamantane; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Insulin, Long-Acting; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Product Surveillance, Postmarketing; Propensity Score; Proportional Hazards Models; Prospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; United States | 2018 |
Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucagon; Glutathione; Glycated Hemoglobin; Insulin; Male; Malondialdehyde; Nitric Oxide; Nitriles; Pancreas; Pioglitazone; Pyrrolidines; Rats, Sprague-Dawley; Streptozocin; Superoxide Dismutase; Thiazolidinediones; Vildagliptin | 2018 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |